For Healthcare Professionals
As a professional, Eisai aims to support you in the treatment of your patients. In this section you will find information including Summary of Product Characteristics (SPC) and Product Information Leaflets (PIL) for our UK products in both Great Britain (GB) and Northern Ireland (NI). If you require further information regarding one of our products, please use the Medical Information Enquiry Form.
Reporting Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/
In the Republic of Ireland please go to www.hpra.ie/.
Alternatively search for the MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Eisai Ltd on one of the options below:
+44 (0)208 600 1400
EUmedinfo@eisai.net
Oncology
Neurology
-
Leqembi®
lecanemab SPC GBRisk minimisation materials PIL GB -
Fycompa®
perampanel SPC Tablets GBSPC Suspension GBSPC Tablets NISPC Suspension NI PIL Tablets GBPIL Suspension GBPIL Tablets NIPIL Suspension NI -
Inovelon®
rufinamide SPC Tablets GBSPC Suspension GBSPC Tablets NISPC Suspension NI PIL Tablets GBPIL Suspension GBPIL Tablets NIPIL Suspension NI -
Aricept®
donepezil hydrochloride SPC PIL -
Aricept Evess®
donepezil hydrochloride SPC PIL